GlobeNewswire: Protalix BioTherapeutics, Inc. Contains the last 10 of 165 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T06:52:59ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/08/30/1909301/0/en/Protalix-BioTherapeutics-Receives-Listing-Deficiency-Letter-from-NYSE-American.html?f=22&fvtc=4&fvtv=13999Protalix BioTherapeutics Receives Listing Deficiency Letter from NYSE American2019-08-30T20:15:00Z<![CDATA[CARMIEL, Israel, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins including a late-stage clinical product expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that it received a deficiency letter from NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the continued listing standards as set forth in Section 1003(a)(i) – (iii) of the NYSE American Company Guide (the “Company Guide”) as it has reported a stockholders’ equity deficiency as of June 30, 2019 and net losses in its five most recent fiscal years ended December 31, 2018.]]>https://www.globenewswire.com/news-release/2019/08/22/1905424/0/en/Protalix-BioTherapeutics-Focuses-on-Evaluating-and-Pursuing-Alternatives-to-Maximize-Shareholder-Value-through-Refinancing-Strategic-Partnerships.html?f=22&fvtc=4&fvtv=13999Protalix BioTherapeutics Focuses on Evaluating and Pursuing Alternatives to Maximize Shareholder Value through Refinancing & Strategic Partnerships2019-08-22T12:45:00Z<![CDATA[CARMIEL, Israel, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that it has engaged a first-tier financial advisory firm to assist the Company in evaluating and pursuing strategic alternatives to maximize stakeholder value.]]>https://www.globenewswire.com/news-release/2019/08/13/1901384/0/en/Shlomo-Yanai-Resigns-as-Chairman-of-the-Board-of-Protalix-BioTherapeutics.html?f=22&fvtc=4&fvtv=13999Shlomo Yanai Resigns as Chairman of the Board of Protalix BioTherapeutics2019-08-13T20:05:00Z<![CDATA[CARMIEL, Israel, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX) today announced that Shlomo Yanai has resigned from the Company’s Board of Directors for personal reasons, effective today. Mr. Yanai has served on the Board of Directors and as the Company’s Chairman of the Board since July 2014. With the announcement of Mr. Yanai’s resignation, the Board of Directors unanimously elected Zeev Bronfeld, a current independent director, as Chairman of the Board.]]>https://www.globenewswire.com/news-release/2019/08/08/1899026/0/en/Protalix-BioTherapeutics-Reports-Second-Quarter-2019-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=13999Protalix BioTherapeutics Reports Second Quarter 2019 Results and Provides Corporate Update2019-08-08T10:05:00Z<![CDATA[CARMIEL, Israel, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced its financial results for the six-month period ended June 30, 2019 and provided a corporate update.]]>https://www.globenewswire.com/news-release/2019/07/29/1893205/0/en/Protalix-BioTherapeutics-to-Hold-Second-Quarter-2019-Financial-Results-and-Corporate-Update-Conference-Call-on-August-8-2019.html?f=22&fvtc=4&fvtv=13999Protalix BioTherapeutics to Hold Second Quarter 2019 Financial Results and Corporate Update Conference Call on August 8, 20192019-07-29T20:01:00Z<![CDATA[CARMIEL, Israel, July 29, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that it will report second quarter 2019 financial results and provide a corporate update on Thursday, August 8, 2019 at 8:30 am ET.]]>https://www.globenewswire.com/news-release/2019/07/29/1892732/0/en/Protalix-BioTherapeutics-Appoints-Eyal-Rubin-as-its-New-Senior-Vice-President-and-Chief-Financial-Officer.html?f=22&fvtc=4&fvtv=13999Protalix BioTherapeutics Appoints Eyal Rubin as its New Senior Vice President and Chief Financial Officer2019-07-29T11:00:00Z<![CDATA[CARMIEL, Israel, July 29, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX) today announced that Eyal Rubin has been appointed to serve as the Company’s new Senior Vice President and Chief Financial Officer, effective September 22, 2019. Yossi Maimon will continue to work with the Company’s finance and accounting teams to ensure a smooth transition of the Company’s financial and accounting functions until Mr. Rubin begins.]]>https://www.globenewswire.com/news-release/2019/06/17/1869487/0/en/Protalix-BioTherapeutics-Completes-Enrollment-in-the-Phase-III-BRIGHT-Clinical-Trial-of-pegunigalsidase-alfa-PRX-102-for-the-Treatment-of-Fabry-Disease.html?f=22&fvtc=4&fvtv=13999Protalix BioTherapeutics Completes Enrollment in the Phase III BRIGHT Clinical Trial of pegunigalsidase alfa (PRX 102) for the Treatment of Fabry Disease2019-06-17T11:00:00Z<![CDATA[CARMIEL, Israel, June 17, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced the completion of enrollment in the phase III BRIGHT clinical trial of pegunigalsidase alfa, or PRX‑102, for the treatment of Fabry disease, via intravenous (IV) infusions of 2 mg/kg administered every 4 weeks. PRX‑102 is the Company’s plant cell-expressed recombinant, PEGylated, cross-linked α‑galactosidase‑A drug candidate.]]>https://www.globenewswire.com/news-release/2019/06/06/1865179/0/en/Protalix-BioTherapeutics-and-Chiesi-Farmaceutici-S-p-A-to-Apply-for-Accelerated-Approval-of-pegunigalsidase-alfa-for-the-Treatment-of-Fabry-Disease-in-the-United-States.html?f=22&fvtc=4&fvtv=13999Protalix BioTherapeutics and Chiesi Farmaceutici S.p.A to Apply for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States2019-06-06T11:00:00Z<![CDATA[BLA Submission Expected First Quarter 2020 BLA Submission Expected First Quarter 2020]]>https://www.globenewswire.com/news-release/2019/05/21/1833240/0/en/Protalix-BioTherapeutics-Appoints-Dror-Bashan-as-its-New-President-and-Chief-Executive-Officer-and-Director.html?f=22&fvtc=4&fvtv=13999Protalix BioTherapeutics Appoints Dror Bashan as its New President and Chief Executive Officer and Director2019-05-21T11:00:00Z<![CDATA[Moshe Manor to continue to serve in the role until June 30, 2019 Moshe Manor to continue to serve in the role until June 30, 2019]]>https://www.globenewswire.com/news-release/2019/05/06/1817322/0/en/Protalix-BioTherapeutics-Reports-2019-First-Quarter-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=13999Protalix BioTherapeutics Reports 2019 First Quarter Results and Provides Corporate Update2019-05-06T11:00:00Z<![CDATA[CARMIEL, Israel, May 06, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced its financial results for the three months ended March 31, 2019 and provided a corporate update.]]>